Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19414597
Xie Z, et al. (2009) Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. Mol Cell Biol 29, 3582-96 19414597
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T183-p - AMPKA1 (human)
Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) increase
metformin increase
2-deoxyglucose increase
leptin increase
acadesine increase
statin increase
metformin increase
PKC-zeta_inhibitor metformin inhibit treatment-induced increase
siRNA metformin inhibit treatment-induced increase PKCZ-siRNA
ONOO(-) increase
PKC-zeta_inhibitor ONOO(-) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

S307-p - LKB1 (human)
Modsite: IRQIRQHsWFRkKHP SwissProt Entrez-Gene
Orthologous residues
LKB1 (human): S307‑p, LKB1 iso2 (human): S307‑p, LKB1 (mouse): S307‑p, LKB1 (rat): S307‑p, LKB1 (pig): S213‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), BAEC (endothelial), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow, human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCZ (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCZ (human) transfection of dominant-negative enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) increase
metformin increase
2-deoxyglucose increase
leptin increase
acadesine increase
statin increase
metformin increase
PKC-zeta_inhibitor metformin inhibit treatment-induced increase
siRNA metformin inhibit treatment-induced increase PKCZ-siRNA
ONOO(-) increase
PKC-zeta_inhibitor ONOO(-) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation
Effect of modification (process):  apoptosis, altered, cell growth, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
AMPKA1 (human) Induces enzymatic activity, induced co-immunoprecipitation
Exportin-1 (human) Induces co-immunoprecipitation
STRAD (human) Induces co-immunoprecipitation
Comments:  in the presence of ONOO(-); supresses angiogenesis;

S428-p - LKB1 (human)
Modsite: SSkIRRLsACkQQ__ SwissProt Entrez-Gene
Orthologous residues
LKB1 (human): S428‑p, LKB1 iso2 (human): , LKB1 (mouse): S431‑p, LKB1 (rat): S431‑p, LKB1 (pig): S339‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), BAEC (endothelial), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow, human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCZ (human) transfection of dominant-negative enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) increase
metformin increase
2-deoxyglucose increase
leptin increase
acadesine increase
statin increase
metformin increase
PKC-zeta_inhibitor metformin inhibit treatment-induced increase
siRNA metformin inhibit treatment-induced increase PKCZ-siRNA
ONOO(-) increase
PKC-zeta_inhibitor ONOO(-) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation
Effect of modification (process):  cell growth, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Exportin-1 (human) Induces co-immunoprecipitation
STRAD (human) Induces co-immunoprecipitation
Comments:  in the presence of ONOO(-); supresses angiogenesis;